Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

October 16, 2018 08:00 ET | Source: Selecta Biosciences, Inc.

Selecta Biosciences to Present New Five Monthly Dose Phase 2 Data for SEL-212 in Chronic, Severe Gout at Upcoming 2018 ACR Annual Meeting

Data continue to suggest sustained serum uric acid (sUA) level reductions and low number of flares over five months of treatmentResults correlated with low or no anti-drug antibodies (ADAs) against...
October 05, 2018 10:01 ET | Source: Selecta Biosciences, Inc.; Généthon

Co-administration of AAV Vectors with SVP-Rapamycin Enables Vector Re-administration in Pre-clinical Gene Therapy Study Published in Nature Communications by Généthon and Selecta Biosciences

Represents a potentially powerful strategy to modulate vector immunogenicity and may open new therapeutic avenues for AAV vector-mediated gene transfer EVRY, France and WATERTOWN, Mass., Oct. 05,...
September 27, 2018 07:30 ET | Source: Selecta Biosciences, Inc.

Selecta Biosciences Appoints Carsten Brunn, Ph.D. as President and Chief Executive Officer

WATERTOWN, Mass., Sept. 27, 2018 (GLOBE NEWSWIRE) -- Selecta Biosciences, Inc. (Nasdaq: SELB), a clinical-stage biopharmaceutical company focused on unlocking the full potential of biologic...
September 25, 2018 08:00 ET | Source: Selecta Biosciences, Inc.

Selecta Biosciences to Present at the Cantor Fitzgerald Global Healthcare Conference on October 02, 2018

WATERTOWN, Mass., Sept. 25, 2018 (GLOBE NEWSWIRE) -- Selecta Biosciences, Inc. (Nasdaq: SELB), a clinical-stage biopharmaceutical company focused on unlocking the full potential of biologic...
September 20, 2018 08:00 ET | Source: Selecta Biosciences, Inc.

Selecta Biosciences to Present at the Jefferies Gene Therapy Summit on September 27, 2018

WATERTOWN, Mass., Sept. 20, 2018 (GLOBE NEWSWIRE) -- Selecta Biosciences, Inc. (Nasdaq: SELB), a clinical-stage biopharmaceutical company focused on unlocking the full potential of biologic...
September 10, 2018 08:00 ET | Source: Selecta Biosciences, Inc.

Selecta Biosciences to Present at the Janney Healthcare Conference on September 17, 2018

WATERTOWN, Mass., Sept. 10, 2018 (GLOBE NEWSWIRE) -- Selecta Biosciences, Inc. (Nasdaq: SELB), a clinical-stage biopharmaceutical company focused on unlocking the full potential of biologic...
August 31, 2018 08:00 ET | Source: Selecta Biosciences, Inc.

Selecta Biosciences Announces Presentation at the 20th Asia Pacific League of Associations for Rheumatology Congress (APLAR)

WATERTOWN, Mass., Aug. 31, 2018 (GLOBE NEWSWIRE) -- Selecta Biosciences, Inc. (Nasdaq: SELB), a clinical-stage biopharmaceutical company focused on unlocking the full potential of biologic therapies...
August 08, 2018 08:00 ET | Source: Selecta Biosciences, Inc.

Selecta Biosciences Announces Second Quarter 2018 Financial Results and Provides Corporate Update

Expanded three-month Phase 2 data presented at EULAR 2018 continue to indicate that SEL-212 product profile may provide better and more sustained serum uric acid control, fewer flares and less...
August 02, 2018 08:00 ET | Source: Selecta Biosciences, Inc.

Selecta Biosciences to Present at the Canaccord Growth Conference on August 9, 2018

WATERTOWN, Mass., Aug. 02, 2018 (GLOBE NEWSWIRE) -- Selecta Biosciences, Inc. (Nasdaq:SELB), a clinical-stage biopharmaceutical company focused on unlocking the full potential of biologic therapies...
August 01, 2018 08:00 ET | Source: Selecta Biosciences, Inc.

Selecta Biosciences Announces Date of Second Quarter 2018 Financial Results Conference Call

WATERTOWN, Mass., Aug. 01, 2018 (GLOBE NEWSWIRE) -- Selecta Biosciences, Inc. (Nasdaq: SELB), a clinical-stage biopharmaceutical company focused on unlocking the full potential of biologic therapies...